

# CITATION REPORT

List of articles citing

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

DOI: 10.1038/nature13108  
Nature, 2014, 506, 445-50.

**Source:** <https://exaly.com/paper-pdf/58891353/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
492	[Cancer and the elusive cancer genes]. <b>2014</b> , 30, 688-92		2
491	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. <b>2014</b> , 5, 10596-606		46
490	Cancer: Tumours outside the mutation box. <i>Nature</i> , <b>2014</b> , 506, 438-9	50.4	47
489	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 863-77	14.3	30
488	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 853-62	14.3	38
487	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 733-41	14.3	96
486	Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPβ. <b>2014</b> , 35, 2404-14		70
485	Highlights from the Literature. <b>2014</b> , 16, 619-621		78
484	Cancer research: quo vadis-to war?. <b>2014</b> , 8, ed45		1
483	50 & 100 Years Ago. <i>Nature</i> , <b>2014</b> , 506, 439-439	50.4	
482	Molecular insights into pediatric brain tumors have the potential to transform therapy. <b>2014</b> , 20, 5630-40		93
481	Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 615-27	14.3	29
480	An epigenetic therapy for diffuse intrinsic pontine gliomas. <b>2014</b> , 20, 1378-9		21
479	A novel pathogenic classification of cancers. <b>2014</b> , 14, 113		9
478	Integrating epigenetics. <b>2014</b> , 395, 1263-4		0
477	Compendium of aberrant DNA methylation and histone modifications in cancer. <b>2014</b> , 455, 3-9		43
476	Reprogramming cancer cells to pluripotency: an experimental tool for exploring cancer epigenetics. <b>2014</b> , 9, 798-802		14

475	Poised chromatin in the mammalian germ line. <b>2014</b> , 141, 3619-26		46
474	Evolution of cancer cell resistance versus intelligent design of epigenetic drugs. <b>2014</b> , 12, 35-39		
473	Development and classes of epigenetic drugs for cancer. <b>2014</b> , 455, 58-69		65
472	The molecular landscape of pediatric brain tumors in the next-generation sequencing era. <b>2014</b> , 14, 474		10
471	Epigenetic regulation leading to induced pluripotency drives cancer development in vivo. <b>2014</b> , 455, 10-5		20
470	ACVR1 mutations in DIPG: lessons learned from FOP. <b>2014</b> , 74, 4565-70		60
469	Epigenetic regulation in cancer progression. <b>2014</b> , 4, 45		78
468	Biological significance of the CpG island methylator phenotype. <b>2014</b> , 455, 35-42		73
467	Epistemology of the origin of cancer: a new paradigm. <b>2014</b> , 14, 331		50
466	DNA methylation in cancer: three decades of discovery. <b>2014</b> , 6, 36		12
465	Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review. <i>Brain Tumor Pathology</i> , <b>2014</b> , 31, 229-33	3.2	19
464	Cancer Bioinformatics. <b>2014</b> ,		4
463	Glioma. <b>2015</b> , 1, 15017		368
462	MethPed: a DNA methylation classifier tool for the identification of pediatric brain tumor subtypes. <b>2015</b> , 7, 62		24
461	Personalized Medicine and Epigenetic Drug Development. <b>2015</b> , 369-386		
460	Molecular dissection of ependymomas. <b>2015</b> , 2, 827-8		14
459	Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. <b>2015</b> , 5, e303		25
458	Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'. <b>2015</b> , 112, 1725-32		174

457	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <b>2015</b> , 27, 728-43	672
456	Oncological Management of Ependymomas. <b>2015</b> , 423-428	
455	An integrative view on sex differences in brain tumors. <b>2015</b> , 72, 3323-42	101
454	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. <b>2015</b> , 16, e293-302	53
453	Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. <b>2015</b> , 3, 1165-74	49
452	Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies. <b>2016</b> , 183, 96-109	18
451	Genome-wide methylation analysis in vestibular schwannomas shows putative mechanisms of gene expression modulation and global hypomethylation at the HOX gene cluster. <b>2015</b> , 54, 197-209	10
450	Towards a systemic paradigm in carcinogenesis: linking epigenetics and genetics. <b>2015</b> , 42, 777-90	25
449	Ependymoma. <b>2015</b> , 67-75	
448	The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis. <b>2015</b> , 26, 1314-24	8
447	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. <b>2015</b> , 16, 280-96	150
446	Epigenetic alterations in cancer and personalized cancer treatment. <b>2015</b> , 11, 333-48	30
445	Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. <b>2015</b> , 75, 924-9	169
444	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. <i>Cancer</i> , <b>2015</b> , 121, 1499-507	6.4 27
443	Molecular biology of pediatric brain tumors and impact on novel therapies. <b>2015</b> , 15, 10	6
442	An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes. <b>2015</b> , 47, 878-87	43
441	Control of cancer formation by intrinsic genetic noise and microenvironmental cues. <i>Nature Reviews Cancer</i> , <b>2015</b> , 15, 499-509	31.3 44
440	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 9704-9	11.5 229

439	Probing the epigenome. <b>2015</b> , 11, 542-5	29
438	Pediatric cancer epigenome and the influence of folate. <b>2015</b> , 7, 961-73	11
437	Pathway and network analysis of cancer genomes. <b>2015</b> , 12, 615-621	235
436	The Emerging Molecular Foundations of Pediatric Brain Tumors. <b>2015</b> , 30, 1838-50	15
435	DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. <b>2015</b> , 34, 5869-78	142
434	Defining the molecular landscape of ependymomas. <b>2015</b> , 27, 613-5	25
433	Translating genomic discoveries to the clinic in pediatric oncology. <b>2015</b> , 27, 34-43	26
432	When one mutation is all it takes. <b>2015</b> , 27, 433-4	28
431	Advances in Management of Pediatric Ependymomas. <b>2015</b> , 17, 47	16
430	Cellular Mechanisms Underlying Intertumoral Heterogeneity. <b>2015</b> , 1, 15-23	27
429	Glioblastoma Stem Cells Respond to Differentiation Cues but Fail to Undergo Commitment and Terminal Cell-Cycle Arrest. <b>2015</b> , 5, 829-842	64
428	microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma. <b>2015</b> , 3, 26	6
427	Translating preclinical hopes into clinical reality for children with ependymoma. <b>2015</b> , 17, 1545-6	1
426	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. <i>Nature Communications</i> , <b>2015</b> , 6, 6044	17.4 120
425	STRUCTURAL BIOLOGY. Chromatin complex, crystal clear. <b>2015</b> , 350, 278-9	
424	DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. <b>2015</b> , 162, 961-73	705
423	Posterior fossa ependymoma: current insights. <b>2015</b> , 31, 1699-706	21
422	Posterior fossa tumors in children: developmental anatomy and diagnostic imaging. <b>2015</b> , 31, 1661-76	48

421	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. <b>2015</b> , 33, 2986-98		138
420	Brain tumors. <b>2015</b> , 62, 167-78		31
419	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <b>2015</b> , 17, 440-7		83
418	Assaying the epigenome in limited numbers of cells. <b>2015</b> , 72, 51-6		15
417	C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. <i>Brain Tumor Pathology</i> , <b>2015</b> , 32, 105-11	3.2	16
416	Tumoral reprogramming: Plasticity takes a walk on the wild side. <b>2015</b> , 1849, 436-47		20
415	Prader-Willi Syndrome: The Disease that Opened up Epigenomic-Based Preemptive Medicine. <b>2016</b> , 4,		3
414	Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays. <b>2016</b> , 2016, 3064643		16
413	Origin of Cancer: An Information, Energy, and Matter Disease. <i>Frontiers in Cell and Developmental Biology</i> , <b>2016</b> , 4, 121	5.7	20
412	DNA methylation analysis of paediatric low-grade astrocytomas identifies a tumour-specific hypomethylation signature in pilocytic astrocytomas. <b>2016</b> , 4, 54		17
411	Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. <b>2016</b> , 11, e0158464		17
410	Clinical Genomics: Challenges and Opportunities. <b>2016</b> , 26, 97-113		7
409	Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. <b>2016</b> , 38, 249-60		20
408	Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. <b>2016</b> , 238, 584-97		23
407	Advances in the biology and treatment of pediatric central nervous system tumors. <b>2016</b> , 28, 34-9		8
406	Somatic Mutation Theory - Why it's Wrong for Most Cancers. <b>2016</b> , 38, 1663-80		43
405	Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism. <i>Nature Communications</i> , <b>2016</b> , 7, 13666	17.4	29
404	Treatment implications of posterior fossa ependymoma subgroups. <b>2016</b> , 35, 93		17

403	Further understanding of the pathology of glioma: implications for the clinic. <b>2016</b> , 16, 1055-65	15
402	Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. <b>2016</b> , 18, 1451-60	68
401	Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers. <b>2016</b> , 5, 13	15
400	Toward an integrated histomolecular diagnosis of supratentorial ependymoma. <b>2016</b> , 18, 893-4	1
399	External signals shape the epigenome. <b>2016</b> , 17, 18	1
398	Molecular classification of gliomas. <b>2016</b> , 134, 97-120	65
397	DREAM: A Simple Method for DNA Methylation Profiling by High-throughput Sequencing. <b>2016</b> , 1465, 111-27	13
396	Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. <b>2016</b> , 76, 5523-37	52
395	Clinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates. <b>2016</b> , 107, 812-9	21
394	Chronic Myeloid Leukemia. <b>2016</b> ,	3
393	Tumour hypoxia causes DNA hypermethylation by reducing TET activity. <i>Nature</i> , <b>2016</b> , 537, 63-68	50.4 354
392	Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathologica</i> , <b>2016</b> , 132, 635-7	14.3 55
391	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 366ra161	17.5 109
390	Targeting the cancer epigenome for therapy. <b>2016</b> , 17, 630-41	649
389	Novel fusion genes and chimeric transcripts in ependymal tumors. <b>2016</b> , 55, 944-953	4
388	Genomic characterization of recurrent high-grade astroblastoma. <b>2016</b> , 209, 321-30	15
387	[Pediatric ependymomas: Current diagnosis and therapy]. <i>Bulletin Du Cancer</i> , <b>2016</b> , 103, 869-879	2.4
386	Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. <b>2016</b> , 6, 1215-1229	41

385	Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. <b>2016</b> , 8, 55		31
384	ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions. <b>2016</b> , 8, 1239-58		16
383	Investigating therapies in ependymoma. <b>2016</b> , 4, 761-773		
382	SMT and TOFT: Why and How They are Opposite and Incompatible Paradigms. <b>2016</b> , 64, 221-39		15
381	Ependymoma: a heterogeneous tumor of uncertain origin and limited therapeutic options. <b>2016</b> , 134, 417-31		13
380	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <b>2016</b> , 34, 2468-77		113
379	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. <b>2016</b> , 35, 1080-9		41
378	Personalised cancer care: promises and challenges of targeted therapy. <b>2016</b> , 109, 98-105		12
377	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2016</b> , 11, 497-521	34	27
376	Next-generation molecular diagnostics. <b>2016</b> , 134, 121-30		1
375	Mutations in chromatin machinery and pediatric high-grade glioma. <b>2016</b> , 2, e1501354		51
374	Biology and management of ependymomas. <b>2016</b> , 18, 902-13		99
373	Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients. <b>2016</b> , 127, 43-52		12
372	Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2016</b> , 11, 283-312	34	72
371	The DNA Methylomes of Cancer. <b>2016</b> , 183-207		1
370	Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia. <b>2016</b> , 76, 2478-89		33
369	Treatment and survival of supratentorial and posterior fossa ependymomas in adults. <b>2016</b> , 28, 24-30		16
368	Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. <b>2016</b> , 17, 284-99		490

367	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <b>2016</b> , 29, 379-393		319
366	Biomarkers in Neoplastic Neuropathology. <b>2016</b> ,		
365	Dynamics inside the cancer cell attractor reveal cell heterogeneity, limits of stability, and escape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 2672-7	11.5	63
364	Biomarkers Applied to Specific Tumor Types. <b>2016</b> , 59-98		
363	An epigenetic gateway to brain tumor cell identity. <b>2016</b> , 19, 10-9		65
362	Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity. <b>2016</b> , 3, e1098791		14
361	The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. <b>2016</b> , 186, 464-77		29
360	Pediatric Ependymoma. <b>2016</b> , 31, 1354-66		21
359	Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. <b>2016</b> , 35, 558-66		99
358	Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives. <b>2017</b> , 54, 15-21		10
357	Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies. <b>2017</b> , 12, 353-369		27
356	DNA methylation signatures in circulating cell-free DNA as biomarkers for the early detection of cancer. <b>2017</b> , 60, 356-362		19
355	Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 445-462	14.3	38
354	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 431-444	14.3	78
353	Glioma Subclassifications and Their Clinical Significance. <b>2017</b> , 14, 284-297		247
352	Bridging the Gaps: iPSC-Based Models from CHIP to MDS to AML. <b>2017</b> , 20, 298-299		0
351	The $\alpha$ -ketoglutarate dehydrogenase complex in cancer metabolic plasticity. <b>2017</b> , 5, 3		51
350	Circulating Tumor DNA as Biomarkers for Cancer Detection. <b>2017</b> , 15, 59-72		134

349	An alternative model for (breast) cancer predisposition. <b>2017</b> , 3, 13	3
348	NF- $\kappa$ B upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. <b>2017</b> , 19, 1350-1360	14
347	H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. <b>2017</b> , 33, 1047-1051	29
346	Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. <b>2017</b> , 17, 310	13
345	DNA methylation and DNA methyltransferases. <b>2017</b> , 10, 23	220
344	Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. <b>2017</b> , 23, 5329-5338	16
343	Ependymomas. <b>2017</b> , 907-916	
342	Molecular mechanisms and therapeutic targets in pediatric brain tumors. <b>2017</b> , 10,	43
341	The cancer epigenome: Concepts, challenges, and therapeutic opportunities. <b>2017</b> , 355, 1147-1152	201
340	Advances in the molecular genetics of gliomas - implications for classification and therapy. <b>2017</b> , 14, 434-452	320
339	Personalized Medicine Through Advanced Genomics. <b>2017</b> , 31-48	1
338	Introduction: Cancer as an Epigenetic Disease. <b>2017</b> , 23, 255-256	3
337	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. <b>2017</b> , 37, 2164-2180	72
336	Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma. <i>Brain Tumor Pathology</i> , <b>2017</b> , 34, 160-164	3.2 7
335	Distinct molecular profile of diffuse cerebellar gliomas. <i>Acta Neuropathologica</i> , <b>2017</b> , 134, 941-956	14.3 29
334	Misregulation of DNA Methylation Regulators in Cancer. <b>2017</b> , 97-124	2
333	Put away your microscopes: the ependymoma molecular era has begun. <b>2017</b> , 29, 443-447	13
332	Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. <b>2017</b> , 135, 201-211	54

331	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. <i>Acta Neuropathologica</i> , <b>2017</b> , 134, 705-714	14.3	114
330	Epigenetic plasticity and the hallmarks of cancer. <b>2017</b> , 357,		551
329	Molecular Basis of Pediatric Brain Tumors. <b>2017</b> , 19, 256-270		9
328	Recent Advances in the Classification and Treatment of Ependymomas. <b>2017</b> , 18, 55		16
327	From Prognostication to Personalized Medicine: Classification of Tumors of the Central Nervous System (CNS) Using Chromosomal Microarrays. <b>2017</b> , 5, 117-124		2
326	Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas. <b>2017</b> , 2, 29		12
325	Precision Oncology: Between Vaguely Right and Precisely Wrong. <b>2017</b> , 77, 6473-6479		42
324	Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors. <i>Nature Communications</i> , <b>2017</b> , 8, 1450	17.4	63
323	Novel - Fusion Gene in Pediatric Ependymomas Discovered by Clonal Expansion of Stem Cells in Absence of Exogenous Mitogens. <b>2017</b> , 77, 5860-5872		14
322	Integrating RNA sequencing into neuro-oncology practice. <b>2017</b> , 189, 93-104		6
321	Characterization of gliomas: from morphology to molecules. <b>2017</b> , 471, 257-269		57
320	Transposase-driven rearrangements in human tumors. <b>2017</b> , 49, 975-977		1
319	Intraventricular Nimodipine for Aneurysmal Subarachnoid Hemorrhage: Results of the NEWTON Phase 1/2a Study. <b>2017</b> , 81, N3-N4		4
318	Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 417-429	14.3	96
317	Molecular Biology of Human Brain Tumors. <b>2017</b> , 657-694		1
316	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 5-12	14.3	202
315	Precision medicine in pediatric oncology: Lessons learned and next steps. <b>2017</b> , 64, e26288		51
314	Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. <b>2017</b> , 64, e26218		61

313	Molecular pathology of paediatric central nervous system tumours. <b>2017</b> , 241, 159-172		45
312	Ependymoma. <i>Pediatric Oncology</i> , <b>2017</b> , 69-92	0.5	2
311	Current therapy and the evolving molecular landscape of paediatric ependymoma. <b>2017</b> , 70, 34-41		50
310	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , <b>2017</b> , 8, 2126	17.4	52
309	Reduced H3K27me3 is a New Epigenetic Biomarker for Pediatric Posterior Fossa Ependymomas. <b>2017</b> , 81, N7-N8		4
308	Ependymoma. <b>2017</b> , 973-978		
307	Identification of endometrial cancer methylation features using combined methylation analysis methods. <b>2017</b> , 12, e0173242		13
306	Epigenetic actions of environmental factors and promising drugs for cancer therapy. <b>2018</b> , 15, 2049-2056		7
305	Insights From Molecular Profiling of Adult Glioma. <b>2017</b> , 35, 2386-2393		40
304	Current Clinical Challenges in Childhood Ependymoma: A Focused Review. <b>2017</b> , 35, 2364-2369		36
303	Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. <b>2017</b> , 35, 2346-2354		21
302	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. <b>2017</b> , 37, 753-763		2
301	Brain Tumors: Challenges and Opportunities to Cure. <b>2017</b> , 35, 2343-2345		17
300	Dynamics and Function of DNA Methylation During Development. <b>2017</b> , 65-94		
299	Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. <b>2018</b> , 14, e7858		35
298	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. <b>2018</b> , 25, 143-171		23
297	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , <b>2018</b> , 555, 321-327	50.4	603
296	Rapid autopsy of a patient with recurrent anaplastic ependymoma. <b>2018</b> , 16, 238-242		2

295	Fitting the epigenome into the picture: methylation classification for paediatric brain tumours. <b>2018</b> , 44, 543-547	
294	The Key Role of Epigenetics in Human Disease Prevention and Mitigation. <b>2018</b> , 378, 1323-1334	290
293	Phylostratigraphic analysis of tumor and developmental transcriptomes reveals relationship between oncogenesis, phylogenesis and ontogenesis. <b>2018</b> , 4, 025002	12
292	Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies. <b>2018</b> , 41, 207-232	55
291	The stem cell division theory of cancer. <b>2018</b> , 123, 95-113	37
290	Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. <b>2018</b> , 4,	10
289	Disruption of circadian clockwork in in vivo reprogramming-induced mouse kidney tumors. <b>2018</b> , 23, 60-69	7
288	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , <b>2018</b> , 553, 101-105	50.4 116
287	Cancer stem cells modulate patterns and processes of evolution in cancers. <b>2018</b> , 33, 1	2
286	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , <b>2018</b> , 555, 469-474	50.4 992
285	A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma. <b>2018</b> , 114, 1499-1511	19
284	Ependymoma. <b>2018</b> , 38, 104-111	27
283	Practical Implications of the Updated WHO Classification of Brain Tumors. <b>2018</b> , 38, 11-18	3
282	Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. <b>2018</b> , 65, e26861	19
281	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. <b>2018</b> , 182, 70-79	16
280	Integrating Molecular Diagnostics With Surgical Neuropathology. <b>2018</b> , 71-89	1
279	Ependymomas and Choroid Plexus Tumors. <b>2018</b> , 145-169	
278	Precision Medicine in Pediatric Neurooncology: A Review. <b>2018</b> , 9, 11-28	7

277	LncRNA LINC00880 promotes cell proliferation, migration, and invasion while inhibiting apoptosis by targeting CACNG5 through the MAPK signaling pathway in spinal cord ependymoma. <b>2018</b> , 233, 6689-6704	7
276	miRNA profiling identifies deregulated miRNAs associated with osteosarcoma development and time to metastasis in two large cohorts. <b>2018</b> , 12, 114-131	34
275	DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. <b>2018</b> , 51, 68-79	22
274	Definition of a minimal genes set for mature lymphoid blood diseases. <b>2018</b> , 24, 27-59	4
273	Ependymal Tumors. <b>2018</b> , 129-144	
272	Potential Epigenetic-Based Therapeutic Targets for Glioma. <b>2018</b> , 11, 408	40
271	Pediatric ependymoma: current treatment and newer therapeutic insights. <b>2018</b> , 14, 3175-3186	6
270	Pediatric Brain Tumor Genetics: What Radiologists Need to Know. <b>2018</b> , 38, 2102-2122	32
269	Posterior Fossa and Brainstem Tumors in Children. <b>2018</b> , 183-203.e7	0
268	Malignant Brain Tumours in Children : Present and Future Perspectives. <b>2018</b> , 61, 402-406	3
267	Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. <b>2018</b> , 6, 134	44
266	Ependymoma. <b>2018</b> , 177-192	1
265	Modern Principles of CNS Tumor Classification. <b>2018</b> , 117-129	
264	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. <i>Cancer</i> , <b>2018</b> , 124, 4168-4180	6.4 30
263	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. <b>2018</b> , 6,	6
262	TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. <b>2018</b> , 25, 1255-1267.e5	17
261	Primary Brain Tumors in Childhood. <b>2018</b> ,	0
260	Introduction to the Special Collection-Beating Cancer with Early Detection: A Seasoned Idea with New Insights. <b>2018</b> , 3, 155-158	

259	A Pediatric Intra-Axial Malignant SMARCB1-Deficient Desmoplastic Tumor Arising in Meningioangiomatosis. <b>2018</b> , 77, 883-889		5
258	Case-based review: ependymomas in adults. <b>2018</b> , 5, 142-153		6
257	Epigenetic Priming in Cancer Initiation. <b>2018</b> , 4, 408-417		55
256	Chemotherapy of Ependymoma in Childhood. <b>2018</b> , 609-619		
255	A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B. <b>2018</b> , 23, 3787-3797		35
254	What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	6
253	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 227-237	14.3	52
252	The asymmetrically segregating lncRNA cherub is required for transforming stem cells into malignant cells. <i>ELife</i> , <b>2018</b> , 7,	8.9	20
251	The dualistic origin of human tumors. <b>2018</b> , 53, 1-16		69
250	Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. <b>2018</b> , 25, 22		104
249	Patient Similarity Networks for Precision Medicine. <b>2018</b> , 430, 2924-2938		48
248	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. <b>2018</b> , 23, 86-100.e6		116
247	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 211-226	14.3	111
246	Cerebellar tumors. <b>2018</b> , 155, 289-299		6
245	Computational morphogenesis - Embryogenesis, cancer research and digital pathology. <b>2018</b> , 169-170, 40-54		8
244	Integrating ependymoma molecular subgroups into clinical trials. <b>2019</b> , 21, 1219-1220		3
243	Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?. <i>Brain Tumor Pathology</i> , <b>2019</b> , 36, 152-161	3.2	6
242	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <b>2019</b> , 36, 51-67.e7		39

241	Microfluidic epigenomic mapping technologies for precision medicine. <b>2019</b> , 19, 2630-2650		7
240	Epigenetic Priming in Immunodeficiencies. <i>Frontiers in Cell and Developmental Biology</i> , <b>2019</b> , 7, 125	5-7	4
239	Minireview: The Epigenetic Modulation of in Reproduction and Cancer. <b>2019</b> , 16,		10
238	A case of intraplacental gestational choriocarcinoma; characterised by the methylation pattern of the early placenta and an absence of driver mutations. <b>2019</b> , 19, 744		8
237	A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations. <i>Brain Tumor Pathology</i> , <b>2019</b> , 36, 162-168	3-2	7
236	The roles of DNA, RNA and histone methylation in ageing and cancer. <b>2019</b> , 20, 573-589		190
235	Challenges and Opportunities for Childhood Cancer Drug Development. <b>2019</b> , 71, 671-697		8
234	Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer. <b>2019</b> , 19, 173		4
233	Molecular Characteristics of Pediatric Ependymomas: A Systematic Review. <b>2019</b> , 1, 861-868		
232	Downregulated long non-coding RNA LINC00899 inhibits invasion and migration of spinal ependymoma cells via RBL2-dependent FoxO pathway. <b>2019</b> , 18, 2566-2579		6
231	Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. <b>2019</b> , 14, 482-517		515
230	Clinical Characteristics and Prognostic Factors of Treatment in Pediatric Posterior Cranial Fossa Ependymoma. <b>2019</b> , 54, 98-107		3
229	Points-to-consider on the return of results in epigenetic research. <b>2019</b> , 11, 31		16
228	Epigenetics in cancer therapy and nanomedicine. <b>2019</b> , 11, 81		86
227	PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. <i>Nature Communications</i> , <b>2019</b> , 10, 2146	17.4	76
226	Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas. <b>2019</b> , 21, 505-515		3
225	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. <i>Nature</i> , <b>2019</b> , 572, 67-73	50.4	149
224	Developmental origins and emerging therapeutic opportunities for childhood cancer. <b>2019</b> , 25, 367-376		51

223	Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation. <i>Cancers</i> , <b>2019</b> , 11,	6.6	75
222	EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. <b>2019</b> , 21, 878-889		65
221	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. <i>Cancer</i> , <b>2019</b> , 125, 1867-1876	6.4	26
220	Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer. <b>2019</b> , 58, 47-55		20
219	Effects of culture condition on epigenomic profiles of brain tumor cells. <b>2019</b> , 5, 1544-1552		10
218	Biomarkers in tumors of the central nervous system - a review. <b>2019</b> , 127, 265-287		8
217	Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment "jigsaw puzzle". <b>2019</b> , 23, 70-85		19
216	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. <b>2019</b> , 24, e921-e929		6
215	Adult Primary Brain Neoplasm, Including 2016 World Health Organization Classification. <b>2019</b> , 57, 1147-1162		4
214	Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort. <b>2019</b> , 7, 181		10
213	Primary Neoplasms of the Pediatric Brain. <b>2019</b> , 57, 1163-1175		7
212	LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target. <i>Cancers</i> , <b>2019</b> , 11,	6.6	32
211	The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies. <b>2019</b> , 3, e169		15
210	Genomic Landscape of Intramedullary Spinal Cord Gliomas. <b>2019</b> , 9, 18722		15
209	A little piece of mind: best practices for brain tumor intraoperative consultation. <b>2019</b> , 32, 44-57		3
208	Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids. <b>2019</b> , 24, 12-24		31
207	Chromatin Accessibility as a Strategy to Detect Changes Associated With Development, Disease, and Exposure and Susceptibility to Chemical Toxins. <b>2019</b> , 85-103		1
206	A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review. <b>2019</b> , 35, 689-694		2

205	Metal carcinogen exposure induces cancer stem cell-like property through epigenetic reprogramming: A novel mechanism of metal carcinogenesis. <b>2019</b> , 57, 95-104	34
204	Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. <b>2019</b> , 144, 1676-1684	28
203	Epigenetic Deregulation in Human Primary Immunodeficiencies. <b>2019</b> , 40, 49-65	14
202	Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma. <b>2019</b> , 68, 305-318	12
201	Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. <b>2019</b> , 141, 449-457	10
200	Epigenetically facilitated mutational assimilation: epigenetics as a hub within the inclusive evolutionary synthesis. <b>2019</b> , 94, 259-282	38
199	The "life code": A theory that unifies the human life cycle and the origin of human tumors. <b>2020</b> , 60, 380-397	41
198	Genetics of Common Pediatric Brain Tumors. <b>2020</b> , 104, 3-12	6
197	Intracranial ependymomas: molecular insights and translation to treatment. <b>2020</b> , 30, 3-12	12
196	Expression and Clinical Significance of Translation Regulatory Long Non-Coding RNA 1 (TRERNA1) in Ependymomas. <b>2020</b> , 26, 1975-1981	3
195	Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine. <b>2019</b> , 10,	34
194	Prognostic value of H3K27me3 in children with ependymoma. <b>2020</b> , 67, e28121	2
193	Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges. <b>2020</b> , 19, 215-228	3
192	TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma. <b>2020</b> , 40, 138-143	1
191	Ependymoma and Chordoma. <b>2020</b> , 87, 860-870	2
190	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. <b>2020</b> , 139, 135-148	12
189	Molecular tumor classification using DNA methylome analysis. <b>2020</b> , 29, R205-R213	2
188	Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B. <b>2020</b> , 140, e320-e327	2

187	Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes. <b>2020</b> , 8, 203		4
186	Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors. <b>2020</b> , 38, 844-856.e7		8
185	DORGE: Discovery of Oncogenes and tumor suppressor genes using Genetic and Epigenetic features. <b>2020</b> , 6,		7
184	Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential. <i>Frontiers in Cell and Developmental Biology</i> , <b>2020</b> , 8, 546	5-7	15
183	CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
182	Single-Cell RNA Sequencing of Childhood Ependymoma Reveals Neoplastic Cell Subpopulations That Impact Molecular Classification and Etiology. <b>2020</b> , 32, 108023		12
181	17 Tumors of the Fourth Ventricle. <b>2020</b> ,		
180	An unexpected diagnosis of paediatric subcutaneous sacrococcygeal extraspinal ependymoma: lessons learnt and review of the literature. <b>2020</b> , 2020, rjaa177		3
179	Weighing ependymoma as an epigenetic disease. <b>2020</b> , 150, 57-61		0
178	Overexpression of Long Noncoding RNA HOTAIR Is a Unique Epigenetic Characteristic of Myxopapillary Ependymoma. <b>2020</b> , 79, 1193-1202		2
177	Illuminating the noncoding genome in cancer.. <b>2020</b> , 1, 864-872		14
176	JNO special issue: an update on pediatric neuro-oncology. <b>2020</b> , 150, 1-4		1
175	Medulloblastoma epigenetics and the path to clinical innovation. <b>2020</b> , 150, 35-46		1
174	Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy. <b>2020</b> , 251, 249-261		21
173	Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome. <b>2020</b> , 36, 2693-2700		6
172	Update on Circumscribed Gliomas and Glioneuronal Tumors. <b>2020</b> , 13, 249-266		2
171	The Epigenetic Progenitor Origin of Cancer Reassessed: DNA Methylation Brings Balance to the Stem Force.. <b>2020</b> , 4,		1
170	Understanding the Deadly Silence of Posterior Fossa A Ependymoma. <b>2020</b> , 78, 999-1001		3

169	cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. <b>2020</b> , 30, 863-866		51
168	Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. <b>2020</b> , 11, 1469		21
167	Sequencing technologies for epigenetics: From basics to applications. <b>2020</b> , 161-183		
166	Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin. <b>2020</b> , 11, 426		2
165	Ependymoma Pediatric Brain Tumor Protein Fingerprinting by Integrated Mass Spectrometry Platforms: A Pilot Investigation. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
164	Invited Review: The role and contribution of transcriptional enhancers in brain cancer. <b>2020</b> , 46, 48-56		2
163	Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response. <b>2020</b> , 22, 1327-1338		4
162	Multiplatform Molecular Profiling Reveals Epigenomic Intratumor Heterogeneity in Ependymoma. <b>2020</b> , 30, 1300-1309.e5		6
161	Epigenetic plasticity of enhancers in cancer. <b>2020</b> , 11, 26-36		7
160	Invited Review: DNA methylation-based classification of paediatric brain tumours. <b>2020</b> , 46, 28-47		13
159	Microsurgical techniques for achieving gross total resection of ependymomas of the fourth ventricle. <b>2020</b> , 120, 149-166		
158	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. <b>2020</b> , 22, 1474-1483		14
157	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. <b>2020</b> , 26, 720-731		60
156	EZH2 inhibitory protein (EZHIP/Cxor67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations. <i>Brain Tumor Pathology</i> , <b>2021</b> , 38, 30-40	3.2	8
155	The genetic landscape of choroid plexus tumors in children and adults. <b>2021</b> , 23, 650-660		3
154	Distinct circular RNA expression profiles in pediatric ependymomas. <b>2021</b> , 31, 387-392		5
153	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. <b>2021</b> , 39, 38-53.e7		18
152	Adult Primary Brain Neoplasm, Including 2016 World Health Organization Classification. <b>2021</b> , 31, 121-138		3

151	Understanding the epigenetic landscape and cellular architecture of childhood brain tumors. <b>2021</b> , 144, 104940		1
150	Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator. <b>2021</b> ,		3
149	Harnessing brain development to understand brain tumours. <b>2021</b> , 148,		2
148	DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology. <b>2021</b> , 23, S16-S29		5
147	Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers. <b>2021</b> , 23, S4-S15		2
146	The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
145	Intracranial ependymomas: The role of advanced neuroimaging in diagnosis and management. <b>2021</b> , 34, 80-92		0
144	Clinical advances in targeting epigenetics for cancer therapy. <b>2021</b> ,		12
143	Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma. <b>2021</b> , 31, e12943		6
142	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <b>2021</b> , 23, 1360-1370		14
141	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. <b>2021</b> , 31, 747-761		4
140	Radiohistogenomics of pediatric low-grade neuroepithelial tumors. <b>2021</b> , 63, 1185-1213		1
139	Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors. <b>2021</b> , 11, 2216-2229		13
138	Capturing scientific knowledge in computable form.		1
137	Methylation and molecular profiles of ependymoma: Influence of patient age and tumor anatomic location. <b>2021</b> , 14, 88		2
136	Ongoing Response in a Multiply Relapsed Metastatic Posterior Fossa Ependymoma A After Vorinostat and Concomitant Irradiation. <b>2021</b> ,		
135	Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis. <b>2021</b> , 19, 174		2
134	A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods. <b>2021</b> , 99, 1101-1113		3

133	Dysregulation of chromatin organization in pediatric and adult brain tumors: oncoepigenomic contributions to tumorigenesis and cancer stem cell properties. <b>2021</b> , 64, 326-336		
132	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. <b>2021</b> , 11, 2230-2247		20
131	Casein kinase 1 (CK1) promotes the proliferation and metastasis of glioma cells via the phosphatidylinositol 3 kinase-matrix metalloproteinase 2 (AKT-MMP2) pathway. <b>2021</b> , 9, 659		2
130	Reconciling Non-Genetic Plasticity with Somatic Evolution in Cancer. <b>2021</b> , 7, 309-322		12
129	Pediatric ependymoma: an overview of a complex disease. <b>2021</b> , 37, 2451-2463		4
128	Targeted Therapy with Sirolimus and Nivolumab in a Child with Refractory Multifocal Anaplastic Ependymoma. <b>2021</b> , 4, 12		0
127	Mechanisms of the synergistic lung tumorigenic effect of arsenic and benzo(a)pyrene combined-exposure. <b>2021</b> , 76, 156-162		3
126	Case Report: Sellar Ependymomas: A Clinic-Pathological Study and Literature Review. <b>2021</b> , 12, 551493		
125	Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups. <b>2021</b> , 7, 565-576		0
124	Pediatric Neuro-Oncology. <b>2021</b> , 39, 829-845		5
123	The DNA methylation landscape of five pediatric-tumor types.		
122	DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker. <b>2021</b> , 13, 176		0
121	Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel. <b>2021</b> , 155, 13-23		
120	The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma. <b>2021</b> , 115, 96-103		2
119	Stem Cells and Cancer Stem Cells: The Jekyll and Hyde Scenario and Their Implications in Stem Cell Therapy. <b>2021</b> , 9,		3
118	Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours. <b>2021</b> , 31, 814-828		5
117	Molecular Stratification of Childhood Ependymomas as a Basis for Personalized Diagnostics and Treatment. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
116	MethylationToActivity: a deep-learning framework that reveals promoter activity landscapes from DNA methylomes in individual tumors. <b>2021</b> , 22, 24		3

115	Origin and Mechanisms of DNA Methylation Dynamics in Cancers. <b>2019</b> , 27-52	2
114	Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1258, 55-75	3.6 2
113	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. <b>2020</b> , 181, 1329-1345.e24	40
112	Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches. <b>2020</b> ,	18
111	Convergence of dispersed regulatory mutations predicts driver genes in prostate cancer.	4
110	Pathway enrichment analysis of -omics data.	4
109	Metabolic adaptations underlie epigenetic vulnerabilities in chemoresistant breast cancer.	2
108	Childhood Cerebellar Tumors Mirror Conserved Fetal Transcriptional Programs.	5
107	Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma. <b>2019</b> , 4,	12
106	Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma. <b>2020</b> , 12, 19	4
105	Genomic sequencing identifies a few mutations driving the independent origin of primary liver tumors in a chronic hepatitis murine model. <b>2017</b> , 12, e0187551	1
104	-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. <b>2017</b> , 1, 55-67	3
103	Common transcriptional programs and the role of chemokine (C-C motif) ligand 20 () in cell migration of cholangiocarcinoma. <b>2020</b> , 19, 154-166	2
102	Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. <b>2016</b> , 7, 86280-86289	20
101	The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors. <b>2017</b> , 8, 2083-2095	11
100	Stem cell cultures derived from pediatric brain tumors accurately model the originating tumors. <b>2017</b> , 8, 18626-18639	19
99	Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids. <b>2018</b> , 9, 28717-28730	14
98	Limitations of current models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. <b>2018</b> , 9, 36530-36541	6

97	Chromatin remodeling defects in pediatric brain tumors. <b>2018</b> , 6, 248		7
96	Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 1328-1350	4.3	8
95	Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment. <b>2017</b> , 15, 116-128		58
94	Treatment Decisions of World Health Organization Grade II and III Ependymomas in Molecular Era. <b>2018</b> , 61, 312-318		7
93	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , <b>2019</b> , 8,	8.9	17
92	Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
91	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. <i>Cancer</i> , <b>2021</b> ,	6.4	11
90	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabc0497	17.5	3
89	Basic Cancer Biology. <b>2014</b> , 1-39		
88	Ependymomas: Genetics. <b>2015</b> , 383-391		
87	Infratentorial Ependymoma. <b>2016</b> , 482-485		
86	Epigenome modifying enzymes regulate development and progression of pancreatic cancers. <i>Suizo</i> , <b>2016</b> , 31, 69-75	0.1	
85	Neuro-Ophthalmologic Manifestations of Systemic and Intracranial Disease. <b>2016</b> , 649-776		
84	Infratentorial Ependymoma. <b>2016</b> , 135		
83	Ependymoma. <b>2016</b> , 106-121		
82	Integrative modeling of tumor DNA methylation identifies a role for metabolism.		
81	Primary Pediatric Brain Tumors of the Posterior Fossa: Part I. <i>Contemporary Clinical Neuroscience</i> , <b>2017</b> , 301-326	0.1	0
80	Temporal and Clonal Progression in a Pediatric Ependymoma Patient Through Multiple Treatments.		

- 79 Ependymoma. **2018**, 165-187
- 78 Phylostratigraphic analysis of tumor and developmental transcriptomes reveals relationship between oncogenesis, phylogenesis and ontogenesis.
- 77 Childhood Ependymoma. *Pediatric Oncology*, **2018**, 257-275 0.5
- 76 Onkologische Grundlagen und Molekulargenetik von ZNS-Tumoren im Kindes- und Jugendalter. **2018**, 347-356
- 75 Neonatal Brain Tumours. **2018**, 969-980
- 74 Genetic Basis and Classification of Cerebral Neoplasms. **2018**, 1-21 0
- 73 Cerebral Gliomas. **2018**, 1-29 0
- 72 Genomic Applications in Brain Tumors. **2019**, 289-308
- 71 PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
- 70 The long non-coding RNAGHSROSreprograms prostate cancer cell lines toward a more aggressive phenotype.
- 69 DNA hypohydroxymethylation in pediatric central nervous system tumors is associated with CTCF binding sites and reduced survival.
- 68 MethylationToActivity: a deep-learning framework that reveals promoter activity landscapes from DNA methylomes in individual tumors.
- 67 Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids. *Current Medicinal Chemistry*, **2020**, 27, 4039-4061 4.3 2
- 66 Circular RNA expression profiles in pediatric ependymomas. 1
- 65 Cell Ecosystem and Signaling Pathways of Primary and Metastatic Pediatric Posterior Fossa Ependymoma.
- 64 Pediatric Brain Tumors. *CONTINUUM Lifelong Learning in Neurology*, **2020**, 26, 1553-1583 3 0
- 63 Genetic Basis and Classification of Cerebral Neoplasms. **2020**, 1775-1791
- 62 Pathway Commons: 2019 Update.

61	Mechanisms of telomere maintenance in pediatric brain tumors: Promising targets for therapy [A narrative review. <i>Glioma (Mumbai, India)</i> , <b>2020</b> , 3, 105	0.3	1
60	Cerebral Gliomas. <b>2020</b> , 1853-1875		
59	Future Therapies for Malignant Brainstem Tumors. <b>2020</b> , 347-392		
58	Radiation Therapy in Ependymal Tumors. <b>2020</b> , 1-13		
57	Cancer aetiology and progression: The crucial link between genome, epigenome and metabolome. <i>Nigerian Journal of Basic and Clinical Sciences</i> , <b>2020</b> , 17, 77	0.2	
56	DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2021</b> ,	34	8
55	DORGE: Discovery of Oncogenes and Tumor Suppressor Genes Using Genetic and Epigenetic Features.		
54	Genomics of adult and pediatric solid tumors. <i>American Journal of Cancer Research</i> , <b>2018</b> , 8, 1356-1386	4.4	12
53	Induced pluripotent stem cells as the source of cancer stem cells providing novel concepts of cancer: gaps between in vitro and in vivo in induced pluripotent stem cells modeling. <b>2022</b> , 265-288		
52	EZH2: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. <i>Acta Neuropathologica</i> , <b>2021</b> , 143, 1	14.3	3
51	Molecular subtyping of ependymoma and prognostic impact of Ki-67. <i>Brain Tumor Pathology</i> , <b>2021</b> , 1	3.2	2
50	Author-sourced capture of pathway knowledge in computable form using Biofactoid. <i>ELife</i> , <b>2021</b> , 10,	8.9	2
49	Pediatric posterior fossa ependymoma and metabolism: A narrative review. <i>Glioma (Mumbai, India)</i> , <b>2021</b> , 4, 85	0.3	
48	Kindliche Hirntumoren bei Erwachsenen: Ependymale Tumoren. <i>Springer Reference Medizin</i> , <b>2021</b> , 1-8	0	
47	Mechanisms of Polycomb group protein function in cancer.. <i>Cell Research</i> , <b>2022</b> ,	24.7	2
46	The biology of ependymomas and emerging novel therapies.. <i>Nature Reviews Cancer</i> , <b>2022</b> ,	31.3	1
45	Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
44	Driver mutations in ADGRL3 are involved in the evolution of ependymoma.. <i>Laboratory Investigation</i> , <b>2022</b> ,	5.9	0

43	Oncohistones: Hijacking the Histone Code. <i>Annual Review of Cancer Biology</i> , <b>2022</b> , 6,	13.3	0
42	Single cell transcriptomics reveals unique metabolic profiles of ependymoma subgroups.. <i>Gene</i> , <b>2022</b> , 820, 146278	3.8	0
41	Ependymal Tumors.. <i>Pediatric and Developmental Pathology</i> , <b>2022</b> , 25, 59-67	2.2	0
40	Network Approaches for Precision Oncology.. <i>Advances in Experimental Medicine and Biology</i> , <b>2022</b> , 1361, 199-213	3.6	
39	Epigenetic mechanisms in paediatric brain tumours: regulators lose control.. <i>Biochemical Society Transactions</i> , <b>2022</b> ,	5.1	0
38	Origin of Cancer: Cell work is the Key to Understanding Cancer Initiation and Progression.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2022</b> , 10, 787995	5.7	2
37	Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications.. <i>Brain Tumor Pathology</i> , <b>2022</b> , 1	3.2	0
36	Essential Management of Pediatric Brain Tumors.. <i>Children</i> , <b>2022</b> , 9,	2.8	0
35	Cancer: More than a geneticist's Pandora's box. <i>Journal of Biosciences</i> , <b>2022</b> , 47,	2.3	
34	Childhood Malignant Brain Tumors: Balancing the Bench and Bedside. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
33	Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
32	Molecular Classification and Therapeutic Targets in Ependymoma.. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
31	Ventricular System. 249-282		
30	Cancer-associated chromatin variants uncover the oncogenic role of transposable elements.. <i>Current Opinion in Genetics and Development</i> , <b>2022</b> , 74, 101911	4.9	1
29	Recurrent ACVR1 mutations in posterior fossa ependymoma.. <i>Acta Neuropathologica</i> , <b>2022</b> ,	14.3	0
28	Pediatric CNS cancer genomics and immunogenomics. <i>Current Opinion in Genetics and Development</i> , <b>2022</b> , 75, 101918	4.9	
27	De quelques théories de l'oncogénèse. <i>Bulletin Du Cancer</i> , <b>2022</b> ,	2.4	
26	Significance of DNA methylation assessment in the morphological diagnosis of brain tumours. <i>Arkhiv Patologii</i> , <b>2022</b> , 84, 65	0.2	0

25	The DNA methylation landscape of five pediatric-tumor types. <i>PeerJ</i> , 10, e13516	3.1	
24	Posterior fossa ependymoma in neurodevelopmental syndrome caused by a de novo germline pathogenic Polr2a variant. <i>American Journal of Medical Genetics, Part A</i> ,	2.5	○
23	Sox9 directs divergent epigenomic states in brain tumor subtypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119,	11.5	○
22	Pro-inflammatory cytokines mediate the epithelial-to-mesenchymal-like transition of pediatric posterior fossa ependymoma. <i>Nature Communications</i> , <b>2022</b> , 13,	17.4	○
21	Corrupted devolution: How normal cells are reborn as cancer precursors. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2022</b> , 149, 106263	5.6	
20	Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort. <b>2022</b> , 10,		○
19	Cancer therapies inducing DNA damage. <b>2022</b> , 205-225		○
18	Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline. 12,		○
17	The Photoluminescence and Vibrational Properties of Black Phosphorous Sheets Chemically/Electrochemically Functionalized in the Presence of Diphenylamine. <b>2022</b> , 14, 4479		○
16	Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas. <b>2022</b> , 13,		○
15	Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.		○
14	Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification. <b>2022</b> , 1-11		○
13	Metabolic determinants of tumour initiation.	2	
12	Ependymomas. <b>2022</b> , 114, 436-446		○
11	Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5. Volume 16, 107-127		○
10	The Role of Epigenetics in Brain and Spinal Cord Tumors. <b>2023</b> , 119-136	1	
9	Transient loss of Polycomb components induces an epigenetic cancer fate.		○
8	Why haven't we solved intracranial pediatric ependymoma? Current questions and barriers to treatment advances.. <b>2023</b> , 39, 100895		○

- 7 Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. **2023**, 11, ○
- 6 Phase II study of everolimus for recurrent or progressive pediatric ependymoma. **2023**, 5, ○
- 5 Primary Pediatric Brain Tumors of the Posterior Fossa: Part I. **2023**, 389-420 ○
- 4 In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma. 13, ○
- 3 Pediatric brain tumors: A neuropathologist's approach to the integrated diagnosis. 11, ○
- 2 lncRNA TRHDE-AS1 correlated with genomic landscape and clinical outcome in glioma. ○
- 1 3D genome mapping identifies subgroup-specific chromosome conformations and tumor-dependency genes in ependymoma. **2023**, 14, ○